Overview:

Summary

“Tuberculosis - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Tuberculosis (TB) drugs market. The report identifies the key trends shaping and driving the global TB market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global TB sector. The global TB drugs market was worth $99m in 2009. The market is expected to decline by 2.8% during the next seven years. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have improved with the conventional DOTs (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB that have lesser treatment durations. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to address the burden of TB in developed and developing nations. With the success of the ongoing clinical studies, the market is expected to witness a breakthrough in TB control and treatment. The vaccines’ primary focus would be to inhibit the infection at the first place. The global TB drugs market is heading towards a phase of decline as no launches are expected till 2016.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Tuberculosis drugs market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action of drugs include ATP synthase inhibitors, protein synthesis inhibitors, cell wall synthesis inhibitors, DNA gyrase inhibitors, FAS synthase inhibitors, translocase-1 inhibitors and others. The vaccine candidates have been segmented as recombinant live vaccines, recombinant protein vaccines and viral vectored vaccines.
- Analysis of the current and future market competition in the global Tuberculosis drugs market. The key market players covered are isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, rifabutin and capreomycin.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with TB.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global tuberculosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global tuberculosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global tuberculosis market landscape? – Identify, understand and capitalize.

Companies Mentioned

TB Alliance, the US
Aeras (Aeras Global TB Vaccine Foundation), the US
Crucell, the Netherlands
Tibotec BVBA, Belgium

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Tuberculosis: Market Characterization 6
2.1 Overview 6
2.2 Tuberculosis Drugs Market Size 6
2.3 Tuberculosis Drugs Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Tuberculosis Drugs Market 8
2.4.1 Drivers for the Tuberculosis drugs market 8
2.4.2 Barriers for the Tuberculosis drugs market 9
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 11
3 Tuberculosis Drugs Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Drugs in the Tuberculosis 13
3.3.1 Isoniazid (INH) 13
3.3.2 Rifampin (RIF) 13
3.3.3 Pyrazinamide (PZA) 14
3.3.4 Ethambutol (EMB) 14
3.3.5 Streptomycin (SM) and Other Aminoglycosides 14
3.3.6 Rifabutin 15
3.3.7 Capreomycin 15
3.4 Key Takeaway 15
4 Tuberculosis Drugs Market: Pipeline Assessment 16
4.1 Overview 16
4.2 Strategic Pipeline Assessment 16
4.2.1 Technology Trends Analytic Framework 16
4.3 Tuberculosis Therapeutics – Promising Drugs under Clinical Development 17
4.4 Molecule Profile for Promising Drugs/Vaccines under Clinical Development 18
4.4.1 Moxifloxacin (TB Alliance) 18
4.4.2 MVA85A/ AERAS-485 (Oxford-Emergent Tuberculosis Consortium Ltd/Aeras) 20
4.4.3 AERAS-402/ Crucell Ad35 (AERAS/ Crucell) 21
4.4.4 TMC207 (Tibotec/TB Alliance) 21
4.4.5 GSK M72 (GlaxoSmithKline (GSK) Biologicals/ Aeras) 22
4.4.6 PA-824 (Chiron/ TB Alliance) 23
4.5 Tuberculosis Drugs Market – Clinical Pipeline by Mechanism of Action 24
4.5.1 Tuberculosis Pipeline – Pipeline by Clinical Phases of Development 25
4.5.2 Tuberculosis Therapeutics – Phase III Clinical Pipeline 25
4.5.3 Tuberculosis Therapeutics – Phase II Clinical Pipeline 25
4.5.4 Tuberculosis Therapeutics – Phase I Clinical Pipeline 26
4.5.5 Tuberculosis Therapeutics – Preclinical Phase Pipeline 26
4.5.6 Tuberculosis Therapeutics – Discovery Pipeline 26
4.6 Key Takeaway 26
5 Tuberculosis Drugs Market: Implications for Future Market Competition 27
6 Tuberculosis Drugs Market: Future Players in the Tuberculosis Market 29
6.1 Introduction 29
6.2 TB Alliance, the US 30
6.2.1 Overview 30
6.2.2 Tuberculosis Portfolio 30
6.3 Aeras (Aeras Global TB Vaccine Foundation), the US 31
6.3.1 Overview 31
6.3.2 Tuberculosis Portfolio 32
6.4 Crucell, the Netherlands 34
6.4.1 Overview 34
6.4.2 Tuberculosis Portfolio 34
6.5 Tibotec BVBA, Belgium 35
6.5.1 Overview 35
6.5.2 Tuberculosis Portfolio 35
7 Tuberculosis Drugs Market: Appendix 37
7.1 Market Definitions 37
7.2 Abbreviations 37
7.3 Research Methodology 38
7.3.1 Coverage 39
7.3.2 Secondary Research 39
7.3.3 Forecasting 40
7.3.4 Primary Research 43
7.3.5 Expert Panel Validation 43
7.4 Contact Us 43
7.5 Disclaimer 43
7.6 Sources 44

1.1 List of Tables
Table 1: Tuberculosis Drugs Market, Global, Market Revenues ($m), 2001-2009 7
Table 2: Tuberculosis Drugs, Global, Market Forecast ($m), 2009-2016 8
Table 3: Tuberculosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010 17
Table 4: Tuberculosis Therapeutics – Phase III Clinical Pipeline, 2010 25
Table 5: Tuberculosis Therapeutics – Phase II Clinical Pipeline, 2010 25
Table 6: Tuberculosis Therapeutics – Phase I Clinical Pipeline, 2010 26
Table 7: Tuberculosis Therapeutics – Preclinical Phase Pipeline, 2010 26
Table 8: Tuberculosis Therapeutics – Discovery Pipeline, 2010 26
Table 9: TB Alliance – Tuberculosis Pipeline Products, 2010 30
Table 10: Aeras – Tuberculosis Pipeline Products, 2010 32
Table 11: Crucell – Tuberculosis Pipeline Products, 2010 34
Table 12: Tibotec – Tuberculosis Pipeline Products, 2010 36

1.2 List of Figures
Figure 1: Tuberculosis Drugs Market, Global, Market Revenues ($m), 2001-2009 7
Figure 2: Tuberculosis Drugs Market, Global, Market Forecast ($m), 2009-2016 8
Figure 3: Opportunity and Unmet Need in the Tuberculosis Drugs Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Marketed Products for Tuberculosis, 2010 12
Figure 5: Technology Trends Analytic Framework of the Tuberculosis Pipeline – 2010 16
Figure 6: Technology Trends Analytic Framework of the Tuberculosis Pipeline – Description, 2010 17
Figure 7: Tuberculosis Drugs Market – Clinical Pipeline by Mechanism of Action, 2010 24
Figure 8: Tuberculosis Pipeline by Phase of Clinical Development, 2010 25
Figure 9: Implications for Future Market Competition in the Tuberculosis Drugs Market, 2010 27
Figure 10: Tuberculosis Market – Clinical Pipeline by Company, 2010 29
Figure 11: GlobalData Methodology 39
Figure 12: GlobalData Market Forecasting Model 42